Treatment of metastatic differentiated thyroid cancer is first based on the use of radioiodine
and thyrotropin-suppressive thyroid hormone treatment. The recent availability of molecular …

The recent availability of molecular targeted therapies leads to reconsideration of the
treatment strategy in patients with distant metastases from differentiated thyroid carcinoma …

Treatment of metastatic differentiated thyroid cancer (DTC) includes the use of radioiodine
and suppressive thyroid hormone treatment. A third of patients with distant metastases (who …

The majority of patients with differentiated thyroid cancer are cured with standard primary
treatments including surgery, radioactive iodine and TSH suppression. A small proportion of …

The spectrum of thyroid cancers ranges from one of the most indolent to one of the most
aggressive solid tumors identified. Conventional therapies for thyroid cancers are based on …

Advanced differentiated thyroid cancer (DTC), defined by clinical characteristics including
gross extrathyroidal invasion, distant metastases, radioiodine (RAI) resistance, and avidity …

Although thyroid carcinoma usually has an excellent prognosis, the lack of therapeutic
options is an issue for patients that develop metastases and are resistant to radioiodine …

The cumulative evidence over the past decades has shown that the incidence of
differentiated thyroid carcinoma (DTC) has exponentially increased. Approximately 10% of …

Most patients treated for differentiated thyroid cancer (DTC) fare quite well. Data from the
Surveillance, Epidemiology, and End Results (SEER) program show that 98.1% of patients …

Differentiated thyroid cancer (DTC) is a rare malignant disease, although its incidence has
increased over the last few decades. It derives from follicular thyroid cells. Generally …